Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MACROGENICS, INC.

(MGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

10/26/2021 | 04:30pm EST

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2021 after the market closes on Tuesday, November 2, 2021.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 2, 2021 at 4:30 pm ET. The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 6063045.

The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. 


CONTACTS:
Christopher James, M.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,  info@macrogenics.com

Primary Logo

Source: MacroGenics, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about MACROGENICS, INC.
11/17Guggenheim Assumes MacroGenics at Buy with $30 Price Target
MT
11/03MacroGenics to Participate in Upcoming Investor Conferences
GL
11/03Wedbush Trims MacroGenics' Price Target to $30 From $32, Keeps Outperform Rating
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
PU
11/02MACROGENICS : Q3 Earnings Snapshot
AQ
11/02MACROGENICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/02Earnings Flash (MGNX) MACROGENICS Posts Q3 Revenue $15.7M
MT
11/02MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Resu..
AQ
11/02MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/26MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
AQ
More news
Analyst Recommendations on MACROGENICS, INC.
More recommendations
Financials (USD)
Sales 2021 84,7 M - -
Net income 2021 -194 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,05x
Yield 2021 -
Capitalization 1 005 M 1 005 M -
Capi. / Sales 2021 11,9x
Capi. / Sales 2022 8,18x
Nbr of Employees 370
Free-Float 93,9%
Chart MACROGENICS, INC.
Duration : Period :
MacroGenics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MACROGENICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 16,40 $
Average target price 36,78 $
Spread / Average Target 124%
EPS Revisions
Managers and Directors
Scott E. Koenig President, Chief Executive Officer & Director
James Karrels Chief Financial Officer, Secretary & Senior VP
Paulo F. Costa Chairman
Ezio Bonvini Chief Scientific Officer & Senior VP-Research
Stephen L. Eck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MACROGENICS, INC.-27.34%1 005
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819